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Abstract: Sarcomas are rare and heterogeneous cancers classically associated with a poor outcome.
Sarcomas are 1% of the cancer but recent estimations indicate that sarcomas account for 2% of the
estimated cancer-related deaths. Traditional treatment with surgery, radiotherapy, and chemotherapy
has improved the outcome for some types of sarcomas. However, novel therapeutic strategies to treat
sarcomas are necessary. TNF-related apoptosis-inducing ligand (TRAIL) is a death ligand initially
described as capable of inducing apoptosis on tumor cell while sparing normal cells. Only few
clinical trials have used TRAIL-based treatments in sarcoma, but they show only low or moderate
efficacy of TRAIL. Consequently, novel TRAIL formulations with an improved TRAIL bioactivity are
necessary. Our group has developed a novel TRAIL formulation based on tethering this death ligand
on a lipid nanoparticle surface (LUV-TRAIL) resembling the physiological secretion of TRAIL as a
trasmembrane protein inserted into the membrane of exosomes. We have already demonstrated that
LUV-TRAIL shows an improved cytotoxic activity when compared to soluble recombinant TRAIL
both in hematological malignancies and epithelial-derived cancers. In the present study, we have
tested LUV-TRAIL in several human sarcoma tumor cell lines with different sensitivity to soluble
recombinant TRAIL, finding that LUV-TRAIL was more efficient than soluble recombinant TRAIL.
Moreover, combined treatment of LUV-TRAIL with distinct drugs proved to be especially effective,
sensitizing even more resistant cell lines to TRAIL.
Keywords: sarcoma; TRAIL; flavopiridol; immunotherapy; lipid nanoparticles
1. Introduction
Sarcomas include a heterogeneous group of complex cancers which derive from mesenchymal
transformed cells. Sarcomas are rare, making up for about 1% of all cancers [1]. It is well known that
prognosis of sarcomas is poor, with a 5-year survival rate of less than 15% when metastasis happens [2].
Over the last years, a great effort for improving treatment outcome has been made, but the complexity
of sarcomas makes that advancements in developing new therapies are extremely slow [3]. Therefore,
there is an urgent need to develop and test novel therapeutic strategies in order to improve prognosis
of sarcoma patients [4]. Among the novel anti-tumor agents used, apoptosis ligand 2/TNF-related
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apoptosis-inducing ligand (Apo2L/TRAIL) has been tested both in pre-clinical studies and clinical
trials in some types of sarcoma [5].
Apoptosis ligand 2/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) is a TNF family
member described as capable of inducing apoptosis in a wide variety of transformed cells while sparing
normal cells [6,7]. This fact made TRAIL to be considered as a promising anti-tumor agent. In fact,
TRAIL-based therapeutic strategies were developed and used in several phase I/II clinical trials on a
wide variety of human cancers [8–10]. However, although TRAIL-based therapies were proven safe,
about 50% of human cancers were intrinsically resistant to TRAIL since the clinical studies using TRAIL
showed limited therapeutic activity of this death ligand in different types of cancer [9,11,12] including
sarcoma [5]. Therefore, novel formulations of TRAIL with improved bioactivity and combination of
TRAIL with sensitizing agents could be plausible strategies to overcome TRAIL resistance [13–16].
Our group generated artificial lipid nanoparticles containing membrane-bound TRAIL
(LUV-TRAIL), resembling the natural TRAIL-containing exosomes physiologically released by
activated human T cells upon re-stimulation [17,18]. We demonstrated that LUV-TRAIL are more
effective than soluble recombinant TRAIL (sTRAIL), inducing apoptosis both in vitro and in vivo in
hematological malignancies [19–21] as well as in epithelial-derived cancers [22–24].
In the present work, we have tested LUV-TRAIL in several human sarcoma cell lines of distinct
origin with different sensitivity to sTRAIL. LUV-TRAIL were more efficient inducing apoptosis in all
sarcoma cells tested than sTRAIL. However, although LUV-TRAIL showed a greater pro-apoptotic
potential compared to sTRAIL, some sarcoma cell lines still remained fairly resistant to LUV-TRAIL.
In this line, a wide range of sensitizing strategies have been described to overcome TRAIL-resistance
in tumor cells. Here, we have tested the therapeutic combination of LUV-TRAIL with several drugs
previously described as sensitizing agents [23–30], in order to improve the pro-apoptotic ability of
LUV-TRAIL. Our results showed that, among all the combinations tested, flavopiridol induced the
strongest sensitizing effect in all sarcoma cell lines tested, by inducing a down-regulation of the
anti-apoptotic protein FLIP.
In summary, LUV-TRAIL showed an improved cytotoxicity against sarcoma cells, overcoming the
intrinsic resistance of these cells to sTRAIL. This was further potentiated when they were combined
with sensitizing agents such as flavopiridol (FVP), opening the door to future clinical applications as
anti-tumor therapy in sarcoma.
2. Results
2.1. LUV-TRAIL Showed an Enhanced In Vitro Cytotoxic Activity Compared to Soluble Recombinant TRAIL
in Human Sarcoma Cells
First, dose-response assays were carried out to compare the in vitro bioactivity of sTRAIL and
LUV-TRAIL, and cell viability was analyzed by the MTT assay (Figure 1a). Whereas A673 cells showed
a great sensitivity both to sTRAIL and LUV-TRAIL, HT-1080 and RD cell lines showed a moderate
sensitivity to sTRAIL However, LUV-TRAIL was capable of inducing a significant decrease of cell
viability both in HT-1080 and RD cells in comparison with sTRAIL. To assess whether the decrease in
cell viability observed after treatment with both forms of TRAIL (sTRAIL and LUV-TRAIL) was due to
the onset of cell death, annexin-V staining was performed (Figure 1b). In all sarcoma cell lines tested,
LUV-TRAIL induced a remarkable increase of cell death at higher dose used (1000 ng/mL) when
compared to sTRAIL. Importantly, the cell death observed in all sarcoma cell lines was specifically
attributable to TRAIL-receptor activation by TRAIL, as cell death was completely inhibited when cells
were pre-incubated with the TRAIL neutralizing antibody RIK2 before treatment with sTRAIL and
LUV-TRAIL (Figure 1b). In this line, LUVs alone (without TRAIL anchoring on their surface), did not
exert any cytotoxic effect in any sarcoma cell lines tested (see black bars on control points in Figure 1b).
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Figure 1. (a) Analysis of cell viability after treatment with LUV-TRAIL on human sarcoma cell lines. 
Dose-response assays using the indicated doses of sTRAIL (ST) and LUV-TRAIL (LT) were performed 
on A673 cells, HT-1080 cells, and RD cells. Cells were treated with ST or LT for 24 h. Then, cell viability 
was measured by the MTT assay method. Graphs show the mean ± SD of at least three independent 
experiments. * p < 0.05, ** p < 0.01, *** p < 0.001; (b) Cytotoxicity assays on human sarcoma cell lines. 
Cells were treated with indicated doses of sTRAIL (ST) or LUV-TRAIL (LT) for 24 h and annexin V 
positive cells were quantified by flow cytometry. When cells were treated with 1000 ng/mL, they were 
previously pre-incubated in presence or absence of the anti-TRAIL blocking mAb, RIK2 (500 ng/mL). 
Graphics show the percentage of annexin-V positive cells analyzed expressed as the mean ± SD of at 
least three experiments. * p < 0.05. (ST versus LT). # p < 0.05, ## p < 0.01 (ST versus ST + RIK2 and, LT 
versus LT + RIK2). TRAIL, TNF-related apoptosis-inducing ligand; LUV-TRAIL, TRAIL on a lipid 
nanoparticle surface; sTRAIL, soluble recombinant TRAIL. 
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2.2. LUV-TRAIL Activated the Caspase Cascade More Efficiently than sTRAIL in Human Sarcoma Cells
Next, the implication of caspases in the cytotoxicity induced by LUV-TRAIL in sarcoma cells was
assessed. For that purpose, sarcoma cells were incubated with sTRAIL or LUV-TRAIL and activation
of the main caspases involved in the extrinsic apoptotic pathway was analyzed by Western blot.
Activation of both caspase-8 and caspase-3 was clearly increased when sarcoma cells were treated with
LUV-TRAIL compared to sTRAIL, as evidenced by the disappearance of the pro-forms of both caspases
(Figure 2a). Moreover, cleavage of the specific caspase-3 substrate, PARP-1, and the specific caspase-8
substrate, Bid, correlated with the activation of both caspases -3 and -8, respectively, indicating a fully
functional activation of the extrinsic apoptotic pathway upon LUV-TRAIL treatment. When time
course assays were performed (Figure 2b), caspase activation was faster in A673 cells when they
were treated with LUV-TRAIL, although, as seen previously, both formulations of TRAIL present
similar cytotoxicity at 24 h. In HT-1080 cells, similar kinetics was observed at shorter times when they
were treated both with sTRAIL and LUV-TRAIL. However, as shown in Figure 2a, caspase activation
was greater when HT-1080 cells were treated with LUV-TRAIL in comparison with sTRAIL after
24 h of treatment. These data reflect that LUV-TRAIL required longer time of incubation to induce
a greater caspase activation and, hence, a greater cytotoxicity than sTRAIL in HT-1080 cells. In case
of RD cells, although no obvious differences could be observed in caspase activation after treatment
with sTRAIL or LUV-TRAIL, Bid and PARP-1 degradation was faster when cells were treated with
LUV-TRAIL. Finally, to fully assess and characterize the role of caspases in LUV-TRAIL induced cell
death, cell death-inhibition assays were performed using the general caspase inhibitor z-VAD-fmk
(Figure 2c). As expected, caspase inhibition fully abrogated cell death induced not only by sTRAIL but
also by LUV-TRAIL. Moreover, when cells were pre-incubated with the specific caspase-8 inhibitor
IETD-fmk, cell death induced by LUV-TRAIL was also fully abrogated, proving that cell death was
fully dependent on the activation of the canonical extrinsic apoptotic pathway, ruling out any other
form of cell death that could be triggered by TRAIL, such as necroptosis.
2.3. Combination of LUV-TRAIL with Anti-Cancer Agents Improved its Cytotoxicity against Human
Sarcoma Cells
Although LUV-TRAIL showed a greater cytotoxic effect than sTRAIL and was able to overcome
sTRAIL resistance in HT-1080 and RD cells, LUV-TRAIL was only capable of inducing a decrease of
cell viability of around 50% in both sarcoma cell lines at the 1000 ng/mL dose. Therefore, we decided
to combine LUV-TRAIL with several anti-cancer agents such as flavopiridol (FVP), doxorubicin (DOX),
trabectedin (TRAB), and bortezomib (BORT) in order to improve LUV-TRAIL-induced cytotoxicity.
First of all, dose-response assays were carried out to analyze the cytotoxic effect of all anti-cancer
agents used alone (Figure 3). Aiming for a sensitizing effect rather than an additive effect, sub-toxic
doses of the different drugs were selected by choosing the maximum concentrations not inducing a
decrease of cell viability greater than 20% (marker doses for each anti-cancer drug in Figure 3).
After that, dose-response assays were carried out by pre-incubating sarcoma cells with the selected
doses of each anti-cancer drug for 2 h before treating with either sTRAIL or LUV-TRAIL.
In the case of A673 cells, although both sTRAIL and LUV-TRAIL induced a great decrease of cell
viability at the highest dose used (1000 ng/mL), all different anti-cancer drugs were able to sensitize to
LUV-TRAIL at intermediate doses (Figure 4a).
In HT-1080 cells, although FVP greatly sensitized to both sTRAIL and LUV-TRAIL, the combination
with LUV-TRAIL was the most cytotoxic (Figure 4b). Combination of TRAIL with DOX sensitized to
both sTRAIL and LUV-TRAIL to the same extent. Similarly, BORT equally sensitized the cells to both
sTRAIL and LUV-TRAIL, whereas TRAB did not show any sensitizing effect whatsoever (Figure 4b).
Finally, in RD cells, combination of both sTRAIL and LUV-TRAIL with FVP or TRAB induced
similar cytotoxocity levels, whereas DOX and BORT did not sensitize to neither sTRAIL nor
LUV-TRAIL (Figure 4c).
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Figure 2. (a) Analysis of caspase activation in human sarcoma cells. Cells were untreated (Control, 
designed as C), or treated with LUVs without TRAIL (LUV), sTRAIL (ST), and LUV-TRAIL (LT) at 
1000 ng/mL for 24 h. After that, cells were lysed, and lysates were subjected to SDS-PAGE and to 
Western blot analysis. Levels of caspase-8, caspase-3, Bid, and PARP-1 were analyzed using specific 
antibodies. Level of actin levels was used as a control for equal protein loading. Cell death was 
measured in parallel by flow cytometry after annexin-V staining (bottom graphs); (b) Analysis of 
time-course caspase activation in human sarcoma cells. Cells were treated with sTRAIL or LUV-
TRAIL at 1000 ng/mL at the indicated times. After that, cells were lysed, and lysates were subjected 
to SDS-PAGE and to Western blot analysis. Levels of caspase-8, caspase-3, Bid, and PARP-1 were 
analyzed using specific antibodies. Level of actin levels was used as a control for equal protein 
loading. Caspase activation was evidenced by the disappearance of the pro-forms shown in the 
Western blot; (c) Analysis of cell death inhibition by caspase inhibition. Human sarcoma cells were 
treated with 1000 ng/mL of both sTRAIL (ST) and LUV-TRAIL (LT) for 24 h previously incubated in 
presence or absence of the pan-caspase inhibitor z-VAD-fmk (30 µM) and of the specific caspase-8 
inhibitor IETD-fmk (30 µM). Graphics show the mean ± SD of the cell death of treated cells expressed 
as percentage of at least three experiments. * p < 0.05. (ST versus LT). ## p < 0.01 (ST versus ST + caspase 
inhibitors and, LT versus LT + caspase inhibitors). 
Figure 2. (a) Analysis of caspase activatio i sarcoma cells. Cells were untr ated (C ntrol,
designed as C), or t eated with LUVs with IL (LUV), sTRAIL (ST), and LUV-TRAIL (LT) at
1000 ng/mL for 24 h. After that, cel s , and lysates w re subj cted to DS-PAGE and to
Western blot analysis. Levels of caspase-8, cas ase-3, id, and PARP-1 were analyzed using specific
antibodies. Level of actin levels was used as a control for equal protein loading. Cell death was
measured in parallel by flow cytometry after annexin-V staining (bottom graphs); (b) Analysis of
time-course caspase activation in human sarcoma cells. Cells were treated with sTRAIL or LUV-TRAIL
at 1000 ng/mL at the indicated times. After that, cells were lysed, and lysates were subjected to
SDS-PAGE and to Western blot analysis. Levels of caspase-8, caspase-3, Bid, and PARP-1 were analyzed
using specific antibodies. Level of actin levels was used as a control for equal protein loading. Caspase
activation was evidenced by the disappearance of the pro-forms shown in the Western blot; (c) Analysis
of cell death inhibition by caspase inhibition. Human sarcoma cells were treated with 1000 ng/mL of
both sTRAIL (ST) and LUV-TRAIL (LT) for 24 h previously incubated in presence or absence of the
pan-caspase inhibitor z-VAD-fmk (30 µM) and of the specific caspase-8 inhibitor IETD-fmk (30 µM).
Graphics show the mean ± SD of the cell death of treated cells expressed as percentage of at least three
experiments. * p < 0.05. (ST versus LT). ## p < 0.01 (ST versus ST + caspase inhibitors and, LT versus LT
+ caspase inhibitors).
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Figure 3. Analysis of the effect of sensitizer agents in cell viability of human sarcoma cells. Dose-
response assays using the sensitizer agents: flavopiridol (FVP), doxorubicin (DOX), trabectedin 
(TRAB), and bortezomib (BORT) were performed on A673 cells (a), HT-1080 cells (b), and RD cells 
(c). Cell viability was assessed by MTT assay after 24 h. The results were expressed as the mean ± SD 
of at least three experiments. Marked doses of each drugs were selected for further experiments of 
sensitization. 
After that, dose-response assays were carried out by pre-incubating sarcoma cells with the 
selected doses of each anti-cancer drug for 2 h before treating with either sTRAIL or LUV-TRAIL. 
In the case of A673 cells, although both sTRAIL and LUV-TRAIL induced a great decrease of cell 
viability at the highest dose used (1000 ng/mL), all different anti-cancer drugs were able to sensitize 
to LUV-TRAIL at intermediate doses (Figure 4a). 
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sensitized to both sTRAIL and LUV-TRAIL to the same extent. Similarly, BORT equally sensitized 
the cells to both sTRAIL and LUV-TRAIL, whereas TRAB did not show any sensitizing effect 
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Figure 4. Analysis of cell viability of human sarcoma cell lines after treatment with sTRAIL or
LUV-TRAIL in combination with sensitizer agents. Cells were pre-incubated for 2 h with sensitizer
drugs: flavopiridol (FVP), doxorubicin (DOX), trabectedin (TRAB), and bortezomib (BORT) at indicated
doses. Afterwards, sTRAIL (ST) or LUV-TRAIL (LT) were added at the indicated concentrations and
left overnight. The following day, cell viability was measured by the MTT assay. In every graph,
the results from treatments with ST and LT in the absence of drugs are superposed in light grey to show
the sensitizing effect more clearly. Graphs show the mean ± SD of at least independent experiments.
Asterisk signs indicate significance between LT alone with LT in combination with a given drug
(* p < 0.05, ** p < 0.005, *** p < 0.001). Pound signs indicate significance between ST alone with ST in
combination with a given drug (# p < 0.05, ### p < 0.005, ### p < 0.001). A673 cells (a), HT-1080 cells (b),
and RD cells (c). Ampersand signs indicate significance between ST in combination with a given drug
with LT in combination with same drug. (& p < 0.05, && p < 0.005, &&& p < 0.001).
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2.4. Combination of FVP with LUV-TRAIL Induced Apoptotic Cell Death and Decreased Long-Term
Clonogenic Survival of Human Sarcoma Cells
According to the results obtained, combination of LUV-TRAIL with FVP greatly enhanced their
cytotoxic ability in all sarcoma cell lines tested. Next, we sought to confirm whether the decrease
of cell viability observed in Figure 4 was due to the induction of apoptosis or to a cytostatic effect.
First, appearance of typical apoptotic features was assessed by microscopy (Figure 5a). In all cases,
cells treated with sTRAIL and LUV-TRAIL alone or in combination with FVP exhibited the typical
apoptotic nuclear morphological changes such as blebbing, nuclear fragmentation, and chromatin
condensation (Figure 5a). Moreover, these nuclear apoptotic morphological changes were more
pronounced when both forms of TRAIL were combined with FVP compared with treatments with
TRAIL alone (both sTRAIL and LUV-TRAIL). Finally, apoptotic morphological changes correlated
in all cases with induction of apoptosis carried out in parallel using annexin V staining (Figure 5a,
showed as percentage of annexin V positive cells below each picture).
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Figure 5. (a) Analysis of nuclear morphological changes after combination of LUV-TRAIL with FVP.
Human sarcoma cells were pre-incubated for 1 h with flavopiridol (FVP, 200 nM for A673 and RD cells,
50 nM for HT-1080 cells). Afterwards, sTRAIL (ST) or LUV-TRAIL (LT) were added (300 ng/mL for
A673 cells and 1000 ng/mL for HT-1080 and RD cells) and left overnight. The following day, nuclear
staining was performing by using Hoechst 33342. As control, cells were untreated (CONTROL) or
treated only with FVP (FVP) at above indicated doses. Original magnification at 400×. Scale bar = 20 µM.
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Cell death was measured in parallel by flow cytometry after annexin-V staining (bottom graphs);
(b) Analysis of clonogenic survival after combination of LUV-TRAIL with FVP. Clonogenic assay was
performed to analyze long-term survival in human sarcoma cells after treatment with sTRAIL (ST)
or LUV-TRAIL (LT) for 24 h (300 ng/mL for A673 cells and 1000 ng/mL for HT-1080 and RD cells).
As indicated, cells were pre-incubated with FVP (FVP, 200 nM for A673 and RD cells, 50 nM for HT-1080
cells) for 1 h. Upper panels show 6-well plates seeded with human sarcoma cells and stained with crystal
violet after 11 days. Bottom panels show the quantification of crystal violet absorbance after solubilizing
in DMSO and measuring absorbance at 550 nm. Graphic shows the mean ± SD of the absorbance of
treated cells expressed as percentage with respect to the untreated cells (control). Asterisk signs indicate
significance between LT and LT (* p < 0.05, ** p < 0.005, *** p < 0.001). Pound signs indicate significance
between TRAIL (ST or LT) alone with TRAIL in combination with FVP (# p < 0.05).
Next, we sought to analyze the long-term cytotoxic effect of the combinations of both forms
of TRAIL alone or in combination with FVP. For this purpose, clonogenic assays were carried out.
(Figure 5b). Notably, liposomes alone (without TRAIL anchored on their surface) were added as
controls to rule out any long-term cytotoxic effect of the lipid nanoparticles (see controls for LUV-TRAIL
in Figure 5b). Treatment with LUV-TRAIL for 24 h significantly delayed clonogenic survival of sarcoma
cells when compared to sTRAIL, indicating that LUV-TRAIL not only showed a greater cytotoxic
short-term effect than sTRAIL but also showed a long-term effect affecting to survival and proliferation
of sarcoma cells. Remarkably, when both forms of TRAIL were combined with FVP, the clonogenic
suvival of sarcoma cells was enhanced compared to TRAIL alone, being again more pronounced in the
case of LUV-TRAIL.
2.5. Combination of FVP with LUV-TRAIL Activated the Caspase Cascade More Efficiently than with sTRAIL
in Human Sarcoma Cells
After assessing the greater cytotoxic effect of the combination of LUV-TRAIL with FVP at both
short and long term, activation of the main caspases involved in the extrinsic apoptotic pathway
(caspase-8 and caspase-3) was analyzed by Western blot. As aforementioned (Figure 2), both sTRAIL
and LUV-TRAIL induced the activation of the extrinsic apoptotic pathway, as shown by the clear
decrease of the pro-forms of both caspases-8 and -3, as well as of Bid and PARP-1, in the three
sarcoma cell lines tested (Figure 6a). Moreover, caspase activation correlated in all cases with
induction of apoptosis as indicated by annexin V staining performed in parallel (Figure 6a, lower
panels). Pretreatment with FVP greatly increased the disappearance of all proteins, proving that
FVP sensitization to both sTRAIL and LUV-TRAIL relies on an enhanced activation of the extrinsic
apoptotic pathway. Importantly, FVP did not induce any detectable caspase activation in any sarcoma
cell tested (Figure 6a, lower panels).
On the other hand, cell death induced by combination of either sTRAIL or LUV-TRAIL with
FVP was fully inhibited by the general caspase inhibitor z-VAD-fmk and the specific caspase inhibitor
IETD-fmk. These data demonstrated that cell death induced by the combination of FVP with TRAIL
(sTRAIL and LUV-TRAIL) was a caspase-dependent apoptotic process through the activation of
the extrinsic apoptotic pathway by caspase-8 (Figure 6b). In this line, cell death induced by the
combination of FVP with both formulations of TRAIL was exclusively dependent of TRAIL since
blocking TRAIL-signaling with the TRAIL-blocking antibody RIK2 entirely abrogated apoptosis
induced by combination of FVP with both sTRAIL and LUV-TRAIL (Figure 6b).
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Figure 6. (a) Caspase activation induced by combined treatments in human breast tumor cells. Cells 
were pre-incubated for 1 h with FVP (200 nM for A673 and RD cells, 50 nM for HT-1080 cells) and 
then treated with indicated doses of sTRAIL (ST) or LUV-TRAIL (LT) overnight. After that, cells were 
lysed and levels of caspase-8, caspase-3, Bid, and PARP-1 were analyzed by Western blot analysis 
using specific antibodies. Actin levels were also determined as a control for equal protein loading 
(upper panels). As control, cells were untreated (C) or treated only with FVP at above indicated doses. 
An aliquot of untreated and treated human sarcoma cells was collected in parallel and apoptosis was 
analyzed by annexin V staining using flow cytometry (lower panels); (b) Analysis of apoptosis 
inhibition by caspase inhibition. Human sarcoma cells were treated with indicated doses of sTRAIL 
(ST) and LUV-TRAIL (LT) previously pre-incubated in presence or absence of FVP (200 nM for A673 
and RD cells, 50 nM for HT-1080 cells). Combined treatment was also performed pre-incubating with 
the TRAIL-blocking antibody RIK2 (500 ng/mL), with the pan-caspase inhibitor z-VAD-fmk (30 µM) 
and with the specific caspase-8 inhibitor IETD-fmk (30 µM). Graphics show the percentage of 
annexin-V positive cells analyzed by flow cytometry as the mean ± SD of at least three experiments. 
** p < 0.01, *** p < 0.001 (ST versus ST + RIK and, LT versus LT + RIK). ## p < 0.01, ### p < 0.001 (ST 
versus ST + caspase inhibitors and, LT versus LT + caspase inhibitors). 
On the other hand, cell death induced by combination of either sTRAIL or LUV-TRAIL with FVP 
was fully inhibited by the general caspase inhibitor z-VAD-fmk and the specific caspase inhibitor 
IETD-fmk. These data demonstrated that cell death induced by the combination of FVP with TRAIL 
(sTRAIL and LUV-TRAIL) was a caspase-dependent apoptotic process through the activation of the 
extrinsic apoptotic pathway by caspase-8 (Figure 6b). In this line, cell death induced by the 
combination of FVP with both formulations of TRAIL was exclusively dependent of TRAIL since 
blocking TRAIL-signaling with the TRAIL-blocking antibody RIK2 entirely abrogated apoptosis 
induced by combination of FVP with both sTRAIL and LUV-TRAIL (Figure 6b). 
Figure 6. (a) Caspase activation induced by combined treatments in human breast tumor cells. Cells
were pre-incubated for 1 h with FVP (200 nM for A673 and RD cells, 50 nM for HT-1080 cells) and
then treated with indicated doses of sTRAIL (ST) or LUV-TRAIL (LT) overnight. After that, cells were
lysed and levels of caspase-8, caspase-3, Bid, and PARP-1 were analyzed by Western blot analysis
using specific antibodies. Actin levels were also determined as a control for equal protein loading
(upper panels). As control, cells were untreated (C) or treated only with FVP at above indicated doses.
An aliquot of untreated and treated human sarcoma cells was collected in parallel and apoptosis
was analyzed by annexin V staining using flow cytometry (lower panels); (b) Analysis of apoptosis
inhibition by caspase inhibition. Human sarcoma cells were treated with indicated doses of sTRAIL
(ST) and LUV-TRAIL (LT) previously pre-incubated in presence or absence of FVP (200 nM for A673
and RD cells, 50 nM for HT-1080 cells). Combined treatment was also performed pre-incubating with
the TRAIL-blocking antibody RIK2 (500 ng/mL), with the pan-caspase inhibitor z-VAD-fmk (30 µM)
and with the specific caspase-8 inhibitor IETD-fmk (30 µM). Graphics show the percentage of annexin-V
positive cells analyzed by flow cytometry as the mean ± SD of at least three experiments. ** p < 0.01,
*** p < 0.001 (ST versus ST + RIK and, LT versus LT + RIK). ## p < 0.01, ### p < 0.001 (ST versus ST +
caspase inhibitors and, LT versus LT + caspase inhibitors).
2.6. FVP Diminished Expression of Anti-Apoptotic Proteins in Human Sarcoma Cells
After assessing the enhanced cytotoxic activity showed by co bined treatments of both TRAIL
formulations with FVP, we analyzed the underlying mechanism of FVP-induced sensitization to TRAIL.
Analysis of FVP effect on the surface expression of pro-apoptotic receptors, DR4 and DR5, and decoy
receptors, DcR1 and DcR2, showed no significant changes of death receptors (DR) upon treatment
with FVP (Figure 7a).
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Therefore, we investigated the expression of different proteins involved in the regulation of
TRAIL-induced apoptosis in sarcoma cells by Western blot. As previously observed, we confirmed that
FVP did not significantly induce apoptosis at the doses used (Figure 7b, bottom panels). Flavopiridol
induced a clear decrease of the anti-apoptotic protein FLIP (mainly cFLIPS) in all sarcoma cell lines
tested (Figure 7b, upper panels). Moreover, in A673 cells a clear decrease of the anti-apoptotic protein
XIAP was observed. Finally, expression of other anti-apoptotic proteins such as Mcl-1 and Bcl-XL did
not vary after FVP treatment in any sarcoma cell line tested (Figure 7b).
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Figure 7. (a) Effect of FVP in death receptor ( R) surface expression in human sarcoma cells. Surface
expression of DR4, DR5, DcR1, and DcR2 in A673, HT-1080, and RD cells untreated (black dotted line)
or treated with 200 nM FVP for 16 h (black line) was analyzed by flow cytometry. Grey dotted line
indicates isotype control and grey histogram indicates unlabeled cells. (b) Effect of FVP in protein
expression in human sarcoma cells. Flavopiridol (FVP) were used at indicated doses was used to treat
human sarcoma cell lines for 16 h. After that, cells 106 cells were lysed and expression of caspase-8,
FLIP, Mcl-1, Bcl-XL, caspase-9, caspase-3, and XIAP were analyzed by Western blot using specific
antibodies. Actin levels were also determined as a control for equal protein loading (upper panels).
An aliquot of untreated and treated human sarcoma cells was collected in parallel and labeled with
annexin-V. Apoptosis was analyzed by flow cytometry (lower panels).
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3. Discussion
Sarcomas are relatively rare malignant tumors of mesenchymal origin and constitute about 1% of
all cancers. Current treatment of sarcomas implies a multidisciplinary approach including surgery,
chemotherapy, and radiotherapy [31]. This has led to an improvement in prognosis of patients with
sarcoma (overall survival about 50%) [32]. However, the implementation of novel therapies could
help to improve the survival of patients suffering from sarcoma in the future. In this line, TRAIL has
been tested in distinct types of sarcoma both in pre-clinical studies and clinical trials [5]. However,
the potential of TRAIL as possible treatment in sarcomas has been explored in all cases using the
soluble form of TRAIL [28,33,34].
Our group previously generated a new TRAIL formulation (LUV-TRAIL) based on tethering
human recombinant TRAIL on the surface of artificial LUV-type liposomes. The improved bioactivity
of LUV-TRAIL has been validated in a broad panel of human cancer cells derived from hematological
malignancies [19–21], as well as epithelial cancer cells both in vitro and in vivo [22–24]. Notably,
although LUV-TRAIL was more cytotoxic than sTRAIL against cancer cells, it lacked toxicity against
normal cells both in vitro [19] and in vivo [23]. The enhanced bioactivity of LUV-TRAIL compared
with sTRAIL relied on its capability of forming supra-trimeric populations of high molecular order
which were not present in sTRAIL [24]. These supra-trimeric populations of high molecular order
present in LUV-TRAIL formulation promoted the clear formation of DR5 oligomers on the target cells.
In short, liposome-bound TRAIL induced superior DR5 clustering, enhancing DISC recruitment and,
consequently, triggering caspase activation more efficiently than the sTRAIL [20,24].
In the present work, we have extended the study of the anti-tumor potential of LUV-TRAIL
to sarcomas. LUV-TRAIL was capable of inducing cell death more efficiently than sTRAIL both
in TRAIL-sensitive sarcoma cells (A673) cells and TRAIL-resistant sarcoma cells (HT-1080 and RD).
Cell death induced by LUV-TRAIL in sarcoma cells was specifically due to TRAIL since pre-incubation
with the neutralizing antibody RIK2 before treatment fully abrogated cell death induced by LUV-TRAIL.
In this line, LUVs without TRAIL anchoring on their surface did not show any cytotoxicity in sarcoma
cells, confirming that LUV-TRAIL-induced cell death was in fact fully attributable to TRAIL. Moreover,
cell death induced by LUV-TRAIL was a caspase-dependent apoptotic process through the activation
of the extrinsic apoptotic pathway by caspase-8 as evidenced by the fact that the pan-caspase inhibitor
zVAD-fmk and the specific caspase-8 inhibitor IETD-fmk completely inhibited LUV-TRAIL-induced
cell death.
It is interesting that in the several studies that have explored the anti-tumor potential of TRAIL
in sarcomas, this death ligand has been used in combination with other drugs, indicating that some
sarcoma types are partially resistant to the sTRAIL [27,28,33,35–37]. In this line, although LUV-TRAIL
showed more pro-apoptotic potential than sTRAIL in sarcoma cell lines, they only induced a moderate
cytotoxic effect in sTRAIL-resistant HT-1080 and RD cells. Therefore, we decided to combine
LUV-TRAIL with several drugs described to sensitize sarcoma cells to TRAIL-induced apoptosis
such as doxorubicin (DOX) [27], trabectedin (TRAB) [28], bortezomib (BORT) [38], and flavopiridol
(FVP). Previous studies of our group on a breast cancer model, sensitization experiments also using
flavopiridol were performed pre-incubating cancer cells before treatment with TRAIL (sTRAIL or
LUV-TRAIL), as well as simultaneous treatment with FVP and both forms of TRAIL [23]. On that
model, no differences were observed when cells were previously treated with FVP and then with
TRAIL in comparison with simultaneous treatment. In this line, other studies carried out by us using
multiple myeloma cells do not show differences between pre-incubation strategy and simultaneous
treatment when TRAIL (sTRAIL or LUV-TRAIL) is combined with drugs (data not shown).
Among them, FVP was proven as the most efficient in the three sarcoma cell lines tested.
Flavopiridol is a semisynthetic flavone that has showed a potent inhibitory effect on cell proliferation
in sarcoma cells [39–41]. Flavopiridol has also been used in clinical trials, and even though was not
effective as monotherapy [42], FVP potentiated the anti-tumor activity of other anti-tumor agents
when was used in combination [43,44].
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Our results demonstrate that FVP greatly sensitized not only to sTRAIL but also, and largely, to
LUV-TRAIL. The cytotoxic effect of LUV-TRAIL in combination with FVP was fully attributed to TRAIL
since the selected doses of FVP did not induce cell death per se. In this line, pre-incubation with the
neutralizing antibody RIK2 fully inhibited cell death induced by the combined treatment. Cell death
induced by the combination of FVP with TRAIL showed the typical morphological changes of apoptotic
cell death such as blebbing, nuclear fragmentation, and chromatin condensation. Furthermore, this
sensitization resulted in an increased activation of both caspase-8 and -3, which was completely
inhibited by the pan-caspase inhibitor z-VAD-fmk and also by the caspase-8 inhibitor IETD-fmk.
Altogether, these data indicate that combination of FVP with LUV-TRAIL was a caspase-dependent
apoptotic process through the activation of the extrinsic apoptotic pathway. Moreover, when
long-term effect of LUV-TRAIL was analyzed, this novel TRAIL formulation inhibited clonogenic cell
growth largely than sTRAIL. Moreover, combination of FVP with both forms of TRAIL, mainly with
LUV-TRAIL, enhanced long-term effect indicating that the combined treatment not only was more
effective at short-term but also was prolonged over time as shown in clonogenic assays.
Several mechanisms have been described to explain FVP-induced TRAIL-sensitization, among
them up-regulation of DR expression [23] or inactivation of anti-apoptotic proteins such as FLIP, XIAP,
Mcl-1, or survivin [25,45,46]. Trying to ascertain the mechanisms involved in the synergy observed
between FVP and LUV-TRAIL, we firstly analyzed DR expression upon FVP treatment. We previously
demonstrated that DR up-regulation was a decisive sensitizing mechanism of FVP to TRAIL-induced
apoptosis in breast cancer cells [23]. However, FVP did not modify either the expression of the
pro-apoptotic TRAIL receptors or that of the decoy receptors in sarcoma cell lines, underscoring that
sensitization mechanisms are different depending on the cancer type studied. In this line, we also
did not observe DR up-regulation in lung cancer cells upon FVP treatment [22]. On the other hand, it
has been described that FVP promotes degradation of anti-apoptotic proteins such as cFLIP, Mcl-1,
and XIAP [25,45,46]. In agreement with previous studies, we observed that FVP induced a clear
decrease of FLIP in all sarcoma cell lines tested. In fact, FVP induced a clear down-regulation of the
short isoform of cFLIP (cFLIPS), while no changes were observed for the long isoform of cFLIP (cFLIPL),
with the exception of A673 cells. It is noteworthy to point out that cFLIPS is considered to be solely an
anti-apoptotic protein promoting caspase-8 inhibition, while the role of cFLIPL is not clear, and seems
that the long isoform of cFLIP promotes or inhibits apoptosis depending on the relative amounts of
both caspase-8 and cFLIPL [47,48]. Interestingly, FVP also induced a clear decrease of XIAP expression
in A463 cells, which also resulted to be the most sensitive cell line to the combined treatment of FVP
with both TRAIL formulations. Although we have not performed specific experiments to address the
precise contribution of XIAP down-regulation to FVP-mediated sensitization to TRAIL, this could at
least partially explain the higher sensitizing effect of FVP in these cells compared to the other cell lines.
Summarizing, this study shows that LUV-TRAIL significantly improves the bioactivity of sTRAIL
on sarcoma cells. Furthermore, the combination of LUV-TRAIL with FVP increased even more the
cytotoxic potential of LUV-TRAIL, opening the door to new TRAIL-sensitization strategies of which
LUV-TRAIL mainly could benefit. In conclusion, the present study validates our novel formulation of
TRAIL based on anchoring this death ligand on liposome surface in sarcoma and could be of relevance
in a future clinical application of TRAIL in this type of cancer.
4. Materials and Methods
4.1. Preparation of Lipid Nanoparticles Decorated with Soluble Recombinant TRAIL
LUV (Large Unilamellar Vesicles)-type lipid nanoparticles with soluble recombinant TRAIL
(sTRAIL) tethered on their surface was performed as previously described [19,49]. Briefly, a mixture
of phosphatidylcholine (PC), sphingomyelin (SM), cholesterol (CHOL), and 1,2-dioleoyl-sn-glycero-
3-{[N-(5-amino-1-carboxypentyl)-iminodiacetic acid]succinyl} (nickel salt) (DOGS-NTA-Ni) (all from
Avanti Polar Lipids, Alabaster, AL; USA) in the weight ratio of 55:30:10:5 were firstly dried under
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a nitrogen and next under vacuum. Lipid mixture with a composition resembling that of natural
exosomes was resuspended in KHE buffer (100 mM KCl, 10 mM HEPES, pH 7.0, containing 0.1 m
MEDTA). After that, resuspended lipids were freeze-thawed 10 times and extruded 10 times through
two polycarbonate membranes with a pore size of 0.2 µm (Whatman, Maidstone, UK) using an
extruder (Northern Lipids, Burnaby, BC, Canada). LUV were incubated in KHE buffer for 30 min
at 37 ◦C with soluble recombinant TRAIL (sTRAIL), corresponding to amino acids 95–281 with a
6-histidine tag in its N-terminal extreme cloned into the pET-28c plasmid (Novagen, kindly provided
by Dr. Marion MacFarlane) [50]. Then LUV with sTRAIL tethered on their surface (LUV-TRAIL)
were ultracentrifugated for 6 h at 100,000 revolutions per minute at 4 ◦C, supernatant was removed,
and finally, the pellet containing LUV-TRAIL was resuspended in an equal volume of sterile KHE buffer.
4.2. Cell Culture and Cytotoxicity Assays
A673 cells (derived from Ewing’s sarcoma), HT-1080 cells (derived from fibrosarcoma), and RD
cells (derived from rhabdomyosarcoma) were obtained from American Type Culture Colection
(ATCC, Manassas, VA, USA). Sarcoma cell lines were routinely cultured in Dulbecco’s Modified
Eagle Medium (DMEM) medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine
and penicillin/streptomycin (i.e., complete medium) at 37 ◦C with a 5% CO2.
4.3. Cell Viability Assays
For cell viability quantification, cells (2.5 × 104 cells/well) were seeded in 96-well plates
(100 µL/well) in complete medium and left overnight to be attached to the bottom. Cells were then
treated with different concentrations (1–1000 ng/mL) of sTRAIL or LUV-TRAIL for 24 h. Cell viability
was evaluated by a modification of 3-[4,5-di-methylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) method of Mosmann as previously described [51]. Data was expressed as the percentage of cell
viability with respect to control cells (untreated cells for sTRAIL, and cells treated with LUVs without
TRAIL for LUV-TRAIL).
4.4. Cytotoxicity Assays
Cytotoxicity assays were performed as follows: 2 × 104 cells were seeded in 96-well plates in
complete medium and left overnight to be attached to the bottom. After that, cells were treated
with different concentrations of sTRAIL or LUV-TRAIL (1–1000 ng/mL) for 24 h. Then, apoptosis
was measured by analyzing phosphatidyl-serine exposure on cell surface was analyzed to quantify
apoptosis. For that, cells were incubated with 0.5 µg/mL annexin-V-APC, Immunostep, Salamanca,
Spain) in annexin-binding buffer (ABB, 140 mM NaCl, 2.5 mM CaCl2, 10 mM HEPES/NaOH, pH 7.4)
for 15 mins at room temperature. Finally, apoptosis quantification was carried out using a FACSCalibur
flow cytometer and CellQuest software (BD Biosciences, Franklin Lakes, NY, USA).
Cell death inhibition assays were carried out by using the blocking anti-human TRAIL mAb
(500 ng/mL, clone RIK2, BD Biosciences), with the pan-caspase inhibitor z-VAD-fmk (30 µM, Bachem,
Bubendorf, Switzerland) or with the specific caspase-8 inhibitor IETD-fmk (30 µM, Bachem). Cells were
pre-incubated with RIK2, z-VAD-fmk, or IET-fmk for 1 h prior to the addition of TRAIL (both sTRAIL
and LUV-TRAIL).
4.5. Clonogenic Assay
Clonogenic survival was analyzed as previously described [22–24]. Briefly, 5000 cells per well
were seeded into 6-well plates and left to be attached to the bottom overnight. The following day, cells
were incubated with sTRAIL or LUV-TRAIL (300 ng/mL for A673 cells and 1000 ng/mL for HT-1080
and RD cells) for 24 h in presence or absence of FVP (50 nM for HT-1080 cells and 200 nM for A673 and
RD cells). Then, culture medium was removed and replaced with fresh medium, and surviving cells
were cultured for 10 days. After that, cells were washed twice with PBS, fixed with pure methanol for
30 min at 4 ◦C, and stained with crystal violet (1% in 50% ethanol). The measurement of the absorbance
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at 550 nm after dissolving crystal violet with DMSO was performed for quantifying the clonogenic
assays. Data were expressed as the percentage of absorbance with respect to the respective control
(untreated cells).
4.6. Western Blot Analysis
The study of the expression of the main proteins involved in the extrinsic apoptotic pathway
was carried out using Western blot analysis as previously described [19–21]. Briefly, cells (5 × 106)
were lysed at 4 ◦C with 100 µL of a buffer containing 1% Triton X-100 and protease and phosphatase
inhibitors. Then, lysated cells were separated by 12% SDS-PAGE, transferred to PVDF membranes,
and blocked with TBS-T buffer (10 mM Tris/HCl, pH 8.0, 0.12 M NaCl, 0.1% Tween-20, 0.05% sodium
azide) containing 5% skimmed milk. PVDF membranes were incubated with mAbs against caspase-8
(BD Biosciences), caspase-3 (Cell Signaling, Danvers, MA; USA), Bid (BD Biosciences), PARP-1
(BD biosciences), caspase-9 (MBL, Woburn, MA; USA), cFLIP (clone NF6, Enzo, Farmingdale, NY,
USA), Mcl-1 (Santa Cruz Biotech, Dallas, TX), Bcl-xL (Cell Signaling), or XIAP (BD Biosciences) in TBS-T
containing 2% skimmed milk. Anti-β-actin mAb (Sigma, Saint Louis, MO; USA) was used as protein
loading control. Pierce ECL Western Blotting Substrate (when used horseradish peroxidase-labeled
secondary antibody, Life Technologies, Carlsbad, CA, USA) or the CDP-Star substrate (when used
phosphatase alkaline-labeled secondary antibody, Merck, Darmstadt, Germany) were used to display
the proteins.
4.7. Surface Expression of Death Receptors
The analysis of surface expression of death receptors was performed as follows: 1 × 105 cells
were incubated with either anti-DR4, anti-DR5, anti-DcR1, anti-DcR2 monoclonal antibodies or isotype
control, all of them PE-conjugated (eBioscience, San Diego, CA, USA) in PBS containing 5% FCS for
30 min at room temperature. Then, cells were analyzed by using a FACSCalibur flow cytometer and
Cell Quest software (BD Biosciences).
4.8. Nuclear Staining
Hoechst 33342 staining was carried out for analyzing the nuclear morphological changes. Briefly,
cells were seeded (105 cells) in 24-well plates in complete medium and incubated in presence or absence
of FVP for 1 h (200 nM for A673 and RD cells and 50 nM for HT-1080 cells). After that, cells were
treated with sTRAIL or LUV-TRAIL (1000 ng/mL) overnight. Then, cells were fixed with 4% PFA for
30 min, washed with PBS, and labeled with 1 µg/mL of Hoechst 33342 (Invitrogen, Dublin, Ireland).
Finally, photographs were taken using a fluorescence microscope (E600/E400, Nikon, Tokio, Japan)
equipped with digital photograph system (DXM 1200F, Nikon) at original magnification at 400×.
4.9. Statistical Analysis
GraphPad Prism 5 software was used to carry out computer-based statistical analysis. Results
showed indicate the mean ± SD of at least three different experiments. Student’s t test for non-paired
variants was performed to evaluate statistical significance. A p < 0.05 value was considered to
be significant.
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